Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Mechanistic basis for the potent anti-angiogenic activity of semaphorin 3F.

Guo HF, Li X, Parker MW, Waltenberger J, Becker PM, Vander Kooi CW.

Biochemistry. 2013 Oct 29;52(43):7551-8. doi: 10.1021/bi401034q. Epub 2013 Oct 18.

2.

Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin.

Parker MW, Hellman LM, Xu P, Fried MG, Vander Kooi CW.

Biochemistry. 2010 May 18;49(19):4068-75. doi: 10.1021/bi100327r.

3.

Mechanism of selective VEGF-A binding by neuropilin-1 reveals a basis for specific ligand inhibition.

Parker MW, Xu P, Guo HF, Vander Kooi CW.

PLoS One. 2012;7(11):e49177. doi: 10.1371/journal.pone.0049177. Epub 2012 Nov 8.

4.

Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1.

Parker MW, Linkugel AD, Vander Kooi CW.

J Mol Biol. 2013 Nov 15;425(22):4405-14. doi: 10.1016/j.jmb.2013.07.017. Epub 2013 Jul 17.

5.

VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation.

Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC.

Mol Biol Cell. 2011 Aug 1;22(15):2766-76. doi: 10.1091/mbc.E09-12-1061. Epub 2011 Jun 8.

6.

Neuropilin-1 enforces extracellular matrix signalling via ABL1 to promote angiogenesis.

Raimondi C.

Biochem Soc Trans. 2014 Oct;42(5):1429-34. doi: 10.1042/BST20140141. Review.

PMID:
25233427
7.

The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.

Nieminen T, Toivanen PI, Rintanen N, Heikura T, Jauhiainen S, Airenne KJ, Alitalo K, Marjomäki V, Ylä-Herttuala S.

Biochim Biophys Acta. 2014 Jan;1840(1):454-63. doi: 10.1016/j.bbagen.2013.10.005. Epub 2013 Oct 8.

PMID:
24112971
8.

Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F.

Geretti E, Shimizu A, Kurschat P, Klagsbrun M.

J Biol Chem. 2007 Aug 31;282(35):25698-707. Epub 2007 Jun 26.

9.

Fetal, but not postnatal, deletion of semaphorin-neuropilin-1 signaling affects murine alveolar development.

Joza S, Wang J, Tseu I, Ackerley C, Post M.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):627-36. doi: 10.1165/rcmb.2012-0407OC.

PMID:
23713442
10.

Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization.

Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cébe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellén L, Klagsbrun M, Claesson-Welsh L.

Blood. 2008 Nov 1;112(9):3638-49. doi: 10.1182/blood-2007-12-125856. Epub 2008 Jul 29.

11.

Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity.

Sulpice E, Plouët J, Bergé M, Allanic D, Tobelem G, Merkulova-Rainon T.

Blood. 2008 Feb 15;111(4):2036-45. Epub 2007 Dec 7.

12.

Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells.

Raimondi C, Fantin A, Lampropoulou A, Denti L, Chikh A, Ruhrberg C.

J Exp Med. 2014 Jun 2;211(6):1167-83. doi: 10.1084/jem.20132330. Epub 2014 May 26.

13.

Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like pro-protein convertases.

Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G.

Cancer Res. 2008 Sep 1;68(17):6922-31. doi: 10.1158/0008-5472.CAN-07-5408.

14.

Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells.

Valdembri D, Caswell PT, Anderson KI, Schwarz JP, König I, Astanina E, Caccavari F, Norman JC, Humphries MJ, Bussolino F, Serini G.

PLoS Biol. 2009 Jan 27;7(1):e25. doi: 10.1371/journal.pbio.1000025.

15.

Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program.

Regano D, Visintin A, Clapero F, Bussolino F, Valdembri D, Maione F, Serini G, Giraudo E.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1710-1721. doi: 10.1161/ATVBAHA.117.308226. Epub 2017 Jul 20.

16.

Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.

Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L.

Cancer Res. 2008 Jun 15;68(12):4683-92. doi: 10.1158/0008-5472.CAN-07-6577.

17.
18.

Exogenous recombinant dimeric neuropilin-1 is sufficient to drive angiogenesis.

Uniewicz KA, Cross MJ, Fernig DG.

J Biol Chem. 2011 Jan 7;286(1):12-23. doi: 10.1074/jbc.M110.190801. Epub 2010 Oct 18.

19.

Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR.

Cébe-Suarez S, Grünewald FS, Jaussi R, Li X, Claesson-Welsh L, Spillmann D, Mercer AA, Prota AE, Ballmer-Hofer K.

FASEB J. 2008 Aug;22(8):3078-86. doi: 10.1096/fj.08-107219. Epub 2008 May 8.

PMID:
18467594
20.

Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion.

Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J.

Neoplasia. 2005 Feb;7(2):180-9.

Supplemental Content

Support Center